A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients - Wikidata - awgldk - TriplyDB

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

http://www.wikidata.org/entity/Q34116591

about

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide Vascular calcification: When should we interfere in chronic kidney disease patients and how?Stop chronic kidney disease progression: Time is approaching Phosphate binders in chronic kidney disease: a systematic review of recent data.Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective.Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.Next-generation phosphate binders: focus on iron-based binders.Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis.Iron-based phosphate binders--a new element in management of hyperphosphatemia.Emerging drugs for secondary hyperparathyroidism.Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders.Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.Advances in pharmacotherapy for secondary hyperparathyroidism.Novel iron-containing phosphate binders for treatment of hyperphosphatemia.Advances in pharmacotherapy for hyperphosphatemia in renal disease.A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Emerging drugs for the treatment of kidney disease-induced anemia.Treating hyperphosphatemia - current and advancing drugs.Phosphate Binders and Targets Over Decades: Do We have it Right Now?Phosphate binders in patients with chronic kidney disease.Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD.The future of phosphate binders: a perspective on novel therapeutics.One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.

P2860

Q26764806-6024B32D-23B0-4D73-970A-DACD232717B8 Q28071582-1D93306F-2C9E-4BC9-9F67-6D2E1ED84E84 Q28078020-338D4EAA-2825-4A23-937A-17F8F5F7C746 Q31039292-18FA5C36-D335-4253-8F40-DC9F634FB5C4 Q33840398-1649F835-6767-44D4-9417-57698DF411AF Q34415635-311777C7-2A9E-492C-824D-5C0304DEAFD5 Q34463433-CEF3FE1A-B97B-489A-B02E-7B83A893D2EC Q35207839-E83C9133-4901-4C97-86F3-113583587896 Q36045060-0A712AA6-C973-482E-A5D2-9162EA19E694 Q36104846-6F7596DA-C019-4C70-B04D-DF6C738F5515 Q36225208-E9F46706-DCE6-4680-B2E7-F2BF1873A64B Q36293813-F58C5FB5-C0F8-4046-8086-BD01950602AD Q36322947-FA123E1A-BA0E-4088-A75F-399F95D436FE Q37204047-2CCD3601-8F2E-416C-8FAA-3D534AA3F888 Q37696553-BF6CC1DA-6173-4D3B-8ED6-2C28C6B95E11 Q38213502-7CDACA27-0D13-49D3-BB8D-654CC0713072 Q38263310-85E3D41E-2B3B-41F1-8ED2-F923B783E14F Q38295285-807D0DFC-5715-4F97-A207-9A82D44D9D2D Q38363615-06A2A6B2-CD7B-4A81-9647-B6D82E742585 Q38374335-D327EE7F-2E28-477E-9E30-9643830BCC34 Q38389206-C5D670A5-D8FF-48DB-A244-C042BEA00545 Q38542710-264115D5-F2AF-4F6E-BFFD-1455198CD152 Q38544533-4DFC1871-978C-40FA-8B0C-C7D81F71DF4F Q38570622-EBBA7C1B-4FC3-43FE-BD48-22CD3BE6440E Q38587575-7A1A903B-4572-4183-993C-45AFD1B3AC09 Q38741675-45B8AD47-459C-467C-BF84-C6F347CAC4D8 Q38819231-03E2E413-0456-43A4-8902-E194F940348D Q38824573-59314316-250E-44BE-B452-586DC64EB92E Q38828902-58CC3E1C-D57F-4D1C-919E-06DFA3F0099A Q38930912-268C5FEA-74DF-4113-8EF2-15600562238E Q38958363-392BF2E5-821C-47B1-893E-87195F4FCD22 Q39033792-9406A3FB-7EE9-4C3A-B7E5-629B8B82C493 Q39155279-55690CFC-ACAD-4E7A-BE33-833BAFB6848A Q39220825-1AB25CB3-F039-40D0-B116-A0564B37CA65 Q39440902-C36DE779-6219-484C-BB1D-41ABD7404190 Q41007103-8E7EA58C-E34B-4DAE-BA71-1D8D0AF77B1B Q43236775-6E561D02-EDBE-4EE5-AC1E-5B7960D0670E Q44090122-79B47110-C81A-4CEB-8459-084BDDAB01FB Q46034498-064CCA5B-766C-4797-B9EE-7BA993DEE0AF Q46547077-6B3D9EE2-9066-418E-A524-A543F07F1F80

P2860

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

http://www.wikidata.org/entity/Q34116591

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

A phase III study of the effic ...... te binder in dialysis patients

@ast

A phase III study of the effic ...... te binder in dialysis patients

@en

A phase III study of the effic ...... te binder in dialysis patients

@nl

type

label

A phase III study of the effic ...... te binder in dialysis patients

@ast

A phase III study of the effic ...... te binder in dialysis patients

@en

A phase III study of the effic ...... te binder in dialysis patients

@nl

prefLabel

A phase III study of the effic ...... te binder in dialysis patients

@ast

A phase III study of the effic ...... te binder in dialysis patients

@en

A phase III study of the effic ...... te binder in dialysis patients

@nl

P1433

Q34116591-4BCE9DCA-145D-49F0-A705-A935EDD4408E

P1476

Q34116591-F8944BCC-DED5-4EBA-84DD-702D5B08677B

P2093

Q34116591-03B2503B-B377-420D-9D82-9B4EF0891478

Q34116591-37E1121D-3312-4E54-9CD7-D46CBC0FE9AF

Q34116591-88FCDB3C-8B97-453D-A01C-F39568626C9F

Q34116591-98CB8B1D-739C-479B-805F-AD8B140185FA

Q34116591-99CF3C57-F2A2-44A8-8C0C-4750C667D33F

Q34116591-CF565EAE-E75C-41DD-B652-449CF94CAE15

Q34116591-D7D2EF4E-458E-44DE-888A-F67640ADDDA3

Q34116591-DB7FB838-0FB1-4E56-808A-7115135DB1A4

Q34116591-FF06A55D-1A25-4925-B938-6C11D39B8064

P2860

Q34116591-11E93AAA-F92D-4FFE-9CAC-60B37FBE7BE1

Q34116591-146B5A93-82FD-4E33-B29D-1D280FCD0152

Q34116591-244FB873-2933-4B2C-BC0D-BFFE34AED538

Q34116591-2C52E2FD-6D9D-4AEC-82F5-616060F500E6

Q34116591-893B9CC8-7EBB-4535-ACF6-6BD543AF91EA

Q34116591-894FC39D-365C-4432-A0EC-92174E9E7A5A

Q34116591-9B16F7F7-A5EF-4250-A789-AEEDB65E62CB

Q34116591-B0534865-76D6-4872-8289-259FB2CDDA38

Q34116591-B2873470-F580-48F3-8E3E-C10529A38122

Q34116591-C633374F-6C3A-4928-BE66-CFAE3669602D

P2888

Q34116591-AB76F35E-A091-48F1-ADA8-BF7D34477077

P304

Q34116591-88EAE1DE-D0DA-42D0-A857-2473AFBB73A5

P31

Q34116591-3806600E-2ACA-44BC-8C33-15E785EEE145

P356

Q34116591-6046E9EB-A0C1-47E6-8A18-53FDDF58C471

P407

Q34116591-11DB0C6C-13A7-44CA-AF97-3684680CB4BD

P433

Q34116591-626AE70B-6F26-4FC0-B08B-4F645D5753DE

P478

Q34116591-A14E6048-1E98-4BB2-9512-F2D20ED762D8

P577

Q34116591-3065A45C-482F-4AFD-ACB2-B9ABF753D1C8

P5875

Q34116591-0D5DFA38-4DA9-419D-A78C-9F9911366817

P6179

Q34116591-FD41F653-A8C4-4C09-A57C-015114FB47EA

P698

Q34116591-FA4E448C-CE50-4C0B-B5BD-B75496151752

P921

Q34116591-430E1382-4FA8-4410-AA99-BF099FB8E0F3

Q34116591-D124D988-385E-4F27-B901-64DD09E030EA

P932

Q34116591-6B0ABCBC-CDCC-4F36-A185-163CEC792A6B

P356

P1433

Kidney International

P1476

A phase III study of the effic ...... te binder in dialysis patients

@en

P2093

Adrian C Covic

http://www.w3.org/2001/XMLSchema#string

Anjay Rastogi

http://www.w3.org/2001/XMLSchema#string

Edward M F Chong

http://www.w3.org/2001/XMLSchema#string

Jürgen Floege

http://www.w3.org/2001/XMLSchema#string

Laura J Lisk

http://www.w3.org/2001/XMLSchema#string

Markus Ketteler

http://www.w3.org/2001/XMLSchema#string

PA21 Study Group

http://www.w3.org/2001/XMLSchema#string

Stuart M Sprague

http://www.w3.org/2001/XMLSchema#string

Sylvain Gaillard

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease.

Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review.

Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis).

Phosphorus binders and survival on hemodialysis.

The roles of the skeleton and phosphorus in the CKD mineral bone disorder

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.

The prevalence of symptoms in end-stage renal disease: a systematic review.

Prevalence and consequences of nonadherence to hemodialysis regimens.

Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients

Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.

P2888

P304

638-647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2014.58

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260949699

http://www.w3.org/2001/XMLSchema#string

P6179

1011704922

http://www.w3.org/2001/XMLSchema#string

P698

24646861

http://www.w3.org/2001/XMLSchema#string

P921

P932

4150998

http://www.w3.org/2001/XMLSchema#string